Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAS825 in Pediatric and Adult Participants With Still's Disease
NCT07203001Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Nov 2025
- Primary completion
- Apr 2027
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of MAS825 in adult-onset Still's disease (AOSD), sponsored by Novartis. Primary endpoint: Number of participants with clinical response based on one set of response criteria at Day 85. Started Nov 2025; status: recruiting.
02
Drugs
MAS825
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NCT07203001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203001.